statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This indicator may be signaling that VALN's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Valneva SE (VALN, $7.68) entered Downtrend as Momentum indicator drops below 0 level on Apr 01, 2024

Valneva SE (NASDAQ:VALN  Get Free Report) was the target of a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 42,400 shares, an...

Short Interest in Valneva SE (NASDAQ:VALN) Increases By 49.8%

Saint-Herblain (France), March 26, 2024 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate the...

Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

Saint-Herblain (France), March 25, 2024 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 22, 2024, of its 2023 Universal...

Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F

Saint-Herblain (France), March 21, 2024 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced it will present on its single-shot chikungunya vaccine, IXCHIQ...

Valneva to Present on its Chikungunya Vaccine IXCHIQ , Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.

Full Year 2023 Valneva SE Earnings Call Transcript

Total revenues of 153.7 million, including product sales of 144.6 million Product sales surpassed pre-pandemic (2019) sales by 12% and 2022 sales by 26%Excluding COVID-19 vaccine sales, product...

Valneva Reports Full Year 2023 Results and  Provides Business Updates and Outlook

Reimbursements deferred by 18 months to start in January 2026 instead of July 2024 Saint-Herblain (France), March 18, 2024 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine...

Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed

For the last three days, A.I.dvisor has detected that VALN's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Valneva SE (VALN, $7.71) Aroon Indicator entered a Downtrend on March 15, 2024.

Valneva SE (VALN, $7.43) Aroon Indicator entered a Downtrend on March 14, 2024.

Valneva SE is a specialty vaccine company, which focuses on the development, manufacturing, and commercialization of prophylactic vaccines for infectious diseases. It operates through the following segments: Commercialized Products, COVID, Vaccine Candidates, and Technologies and Services. The Commercialized Products segment markets vaccines, currently IXIARO and DUKORAL vaccines, as well as third-party products. The COVID segment develops, manufactures, and distribute related to COVID-19 vaccine candidate, VLA2001. The Vaccine Candidates segment focuses on proprietary research and development programs aiming to generate new approvable products to generate future cash flows from product sales or from commercialization through partnering with pharmaceutical companies. The Technologies and Services segment offers services and inventions at a commercialization stage. The company was founded on April 7, 1999 and is headquartered in Saint-Herblain, France.

Watchers	2,061
52-Wk Low	$6.58
52-Wk High	$17.05

Volume	5,648.00
52-Wk High	$17.05
52-Wk Low	$6.58

Period	Estimated	Reported	Surprise	Result
Q1'24	$0.97	--	--	N/A
Q4'23	-$0.00	--	--	N/A
Q3'23	-$0.30	--	--	N/A
Q2'23	-$0.28	--	--	N/A
Q1'23	-$0.39	-$0.29	26.21%	BEAT

VALN Valneva SE - ADR

About

Feed

News

Earnings

Fundamentals